ArticleDiabetes, obesity & metabolism2026
Sustained Use of SGLT2 Inhibitors and Cardiovascular Outcomes in Older Adults: A Landmark Cohort Study.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sustained Use of SGLT2 Inhibitors and Cardiovascular Outcomes in Older Adults: A Landmark Cohort Study.Diabetes, obesity & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimsTo examine adjusted cardiovascular outcome associations among older adults with type 2 diabetes who had sustained sodium-glucose cotransporter 2 inhibitor (SGLT2i) or dipeptidyl peptidase-4 inhibitor (DPP-4i) therapy for ≥ 6 months, focusing on the maintenance phase and heterogeneity across body mass index (BMI) strata. MATERIALS AND
methodsWe conducted a nationwide-scale landmark cohort study using linked claims and health examination data in Japan. Adults aged ≥ 65 years with type 2 diabetes who maintained SGLT2i or DPP-4i for ≥ 6 months were included. Weighted discrete-time hazard models with inverse probability of treatment and censoring weighting were applied.
resultsAmong 24 380 participants (4223 SGLT2i; 20 157 DPP-4i), sustained SGLT2i use was associated with lower hazards of heart failure hospitalisation (HR, 0.775; 95% CI, 0.628-0.958) and MACE (myocardial infarction, stroke or all-cause mortality) (HR, 0.848; 95% CI, 0.753-0.955). Stroke hazard was lower (HR, 0.834; 95% CI, 0.721-0.965), whereas myocardial infarction and all-cause mortality were not clearly different. The association for heart failure hospitalisation was directionally consistent across BMI strata (p for interaction = 0.953), whereas MACE estimates differed across BMI strata (p for interaction = 0.007), with no clear association in the lowest BMI group (< 22 kg/m
conclusionsAmong older adults who had maintained treatment for ≥ 6 months, sustained SGLT2i use was associated with lower subsequent risks of heart failure hospitalisation and MACE. Heart failure associations were directionally consistent across BMI strata, whereas BMI-related MACE heterogeneity was exploratory and should not be interpreted as evidence to guide treatment by BMI alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.